Schorndorf, Germany, August 24, 2010 — Catalent Pharma Solutions, a leading provider of innovative solutions for the global pharmaceutical industry, has successfully worked with BioAlliance Pharma on the development, approval and launch of Miconazole 50mg buccal tablets for the local treatment of oropharyngeal candidiasis. The product, which has been on the market in several European countries since 2007 under the name Loramyc®, was approved on April 16, 2010 by the FDA and has now been successfully launched in the U.S., under the trade name Oravig™, by Strativa Pharmaceuticals Inc., a division of Par Pharmaceuticals.
For nearly 50 years, Catalent’s operations in Schorndorf, Germany has provided a broad range of services to global, regional and local pharmaceutical customers. Today, Catalent provides oral dosage form development, manufacturing and packaging services, as well as comprehensive supply chain solutions. In the fall of 2009, Catalent’s Schorndorf facility successfully completed an FDA inspection adding to a long track record of regulatory compliance, including German and other EU and international regulatory authorities.
“The launch of Oravig™ on the US market is a major step for BioAlliance, as it opens up the largest market worldwide. We are pleased to share this success with Catalent who has ensured the industrial development through a close collaboration with our teams” declares Dominique Costantini, CEO of BioAlliance Pharma.
“We are proud that we could once again prove that we are the preferred partner for pharmaceutical companies which are looking for innovative solutions for solid oral dose formulations for any market in the world,” said Eric Schmidhaeuser, Managing Director of the Schorndorf operation.
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,000 people at 30 facilities worldwide and in fiscal 2009 generated more than $1.6 billion in annual revenue.
more products. better treatments. reliably supplied.™
About BioAlliance Pharma
Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and radiotherapy-induced complications and opportunistic infections in immunocompromised patients, BioAlliance conceives and develops innovative products, especially in the hospital setting and for orphan or rare diseases. With its targeted approaches, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams capitalize on key competencies required to identify, develop and register drugs in Europe and the USA.
About Strativa Pharmaceuticals
Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE:PRX), excels at finding, enhancing, and bringing to market drugs that make a meaningful difference to patients.
About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a US-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.
LORAMYC is a registered trademark of Bioallance Pharma
ORAVIG is a trademark of Par Pharmaceutical Co., Inc.